Literature DB >> 6269292

Mechanism of inhibition of Epstein-Barr virus replication by phosphonoformic acid.

A K Datta, R E Hood.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6269292     DOI: 10.1016/0042-6822(81)90251-8

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


× No keyword cloud information.
  11 in total

1.  The Epstein-Barr virus lytic program is controlled by the co-operative functions of two transactivators.

Authors:  R Feederle; M Kost; M Baumann; A Janz; E Drouet; W Hammerschmidt; H J Delecluse
Journal:  EMBO J       Date:  2000-06-15       Impact factor: 11.598

Review 2.  Resistance of herpes simplex viruses to nucleoside analogues: mechanisms, prevalence, and management.

Authors:  Jocelyne Piret; Guy Boivin
Journal:  Antimicrob Agents Chemother       Date:  2010-11-15       Impact factor: 5.191

3.  A functionally distinct TATA box required for late progression through the Epstein-Barr virus life cycle.

Authors:  T R Serio; N Cahill; M E Prout; G Miller
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

4.  Late gene expression from the Epstein-Barr virus BcLF1 and BFRF3 promoters does not require DNA replication in cis.

Authors:  T R Serio; J L Kolman; G Miller
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

5.  Development of drugs for Epstein-Barr virus using high-throughput in silico virtual screening.

Authors:  Ning Li; Scott Thompson; Hualiang Jiang; Paul M Lieberman; Cheng Luo
Journal:  Expert Opin Drug Discov       Date:  2010-12       Impact factor: 6.098

6.  Identification and characterization of a DNase induced by Epstein-Barr virus.

Authors:  R S Tan; A K Datta; Y C Cheng
Journal:  J Virol       Date:  1982-12       Impact factor: 5.103

Review 7.  Foscarnet. A review of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with cytomegalovirus retinitis.

Authors:  P Chrisp; S P Clissold
Journal:  Drugs       Date:  1991-01       Impact factor: 9.546

8.  Interaction of Epstein-Barr virus DNA polymerase with aphidicolin, phosphonoformate and 5'-GMP.

Authors:  J S Li; Y C Cheng
Journal:  Virus Genes       Date:  1988-07       Impact factor: 2.332

Review 9.  Foscarnet. A reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections.

Authors:  A J Wagstaff; H M Bryson
Journal:  Drugs       Date:  1994-08       Impact factor: 9.546

10.  Inhibition of Epstein-Barr virus replication by a benzimidazole L-riboside: novel antiviral mechanism of 5, 6-dichloro-2-(isopropylamino)-1-beta-L-ribofuranosyl-1H-benzimidazole.

Authors:  V L Zacny; E Gershburg; M G Davis; K K Biron; J S Pagano
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.